Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease
about
Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetesSerum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophagesElevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population.Plasma-free fatty acids, fatty acid-binding protein 4, and mortality in older adults (from the Cardiovascular Health Study).Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity.Urinary excretion of fatty acid-binding protein 4 is associated with albuminuria and renal dysfunction.Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases.Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general populationElevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectorisPossible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor.Transcriptome and Metabolome Analyses in Exogenous FABP4- and FABP5-Treated Adipose-Derived Stem CellsElevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevationReduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus.Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters.Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study.Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease.Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production.Cytokine-like Activity of Liver Type Fatty Acid Binding Protein (L-FABP) Inducing Inflammatory Cytokine Interleukin-6.Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?Inflammation and diabetes-accelerated atherosclerosis: myeloid cell mediators.Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment.Serum adipocyte-fatty acid binding protein (FABP4) levels in women from Mexico exposed to polycyclic aromatic hydrocarbons (PAHs).Post-weaning high-fat diet accelerates kidney injury, but not hypertension programmed by maternal diabetes.RNA-seq analysis of the kidneys of broiler chickens fed diets containing different concentrations of calcium.Ectopic Fatty Acid-Binding Protein 4 Expression in the Vascular Endothelium is Involved in Neointima Formation After Vascular Injury.Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention.Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension.FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms.Serum Concentrations of New Predictive Cardiovascular Disease Biomarkers in Mexican Women Exposed to Lead.FABP4 and Cardiovascular Events in Peripheral Arterial Disease.Serum adipocyte fatty acid-binding protein level is associated with arterial stiffness quantified with cardio-ankle vascular index in kidney transplant patients.Association between Q192R paraoxonase 1 polymorphism and serumadipocyte-fatty acid binding protein (FABP4) levels in Mexican women.Circulating FABP4 is eliminated by the kidney via glomerular filtration followed by megalin-mediated reabsorption
P2860
Q27703246-A8C3F997-1978-451C-84DB-1EFB0CBCA83FQ33669547-E621BA90-F3BE-4D47-9D82-B4E1CF70A04EQ34103605-CC165B86-6E3E-4B20-A7A6-B6BD56EBA9B9Q34173625-2431CD26-9517-41CA-8A05-B8A9EDE2BA8AQ34455370-E6B65CC4-2ACF-4AD2-9B67-D52FEF4BB6B7Q34704298-A47F6D96-080A-4B6E-A425-6EB47B293B05Q35042217-B5DDB4FD-736B-4584-83C7-C91C088CA57DQ35054010-6050518A-A0BD-4A9C-A28C-FE0C98BCD9B4Q35963358-1CE8DB24-AD0E-4257-B52D-8344D2166D94Q36001903-1CC433BF-41CA-461E-BBA3-B2F993B41FF2Q36218431-30AAD586-CBD4-4C47-BF1E-C650C6868E74Q36254291-57301205-C6CD-4F66-ACF2-BDE81041C9FAQ36307279-AAC17598-47EE-4FE8-86E4-B78C29D37D9FQ36454709-D55292F3-1E8C-4457-84AC-49E0C1A907A9Q36701727-243BEB63-FB2C-4256-927D-80382C61F4EFQ37070686-9B37758F-DCEB-4A40-9CFD-A4B9EAEB4466Q37127299-21E69338-6A1F-4409-AA73-640F184CF699Q37378495-CD988425-BF46-4552-9FCF-C1541DEE3FFEQ38050907-947267A0-A67F-4A20-9431-7860A47A0087Q38059912-56E09AD8-BE26-4441-BD2F-0C502458EC4DQ38872713-D96672D9-A6F7-4EB4-8993-8CE03A231B32Q39233265-0C928015-5859-417A-8592-F73C6F38F195Q40318979-B5A10E80-C4F3-4580-890B-645811C1F161Q41717850-6BD0376A-6706-44EB-AB0F-62E86D23768BQ42373725-743C05A4-8107-48C0-8057-1415E828E508Q42374545-256AFD4A-95D2-45AB-938F-484D18E2FE1BQ42830503-CCD05CF1-E45B-4916-9BFA-39F16D700596Q42832081-A8D164C5-74CB-4B27-BBF8-7AAF32F23DB5Q47267706-79E9DFA1-745F-4BE4-B3BA-EFF5FDFBD56EQ47895980-D6609C9D-5B55-4519-BFB8-2ACF7CEB4FA1Q47976365-84EB2DB5-4B43-47A7-87FB-C8ED87E56F77Q51422848-DCDA11B1-ED67-4223-B973-6D91FBCE0B14Q58608864-C401AF1E-15A3-42F4-A583-79BAF5B69720
P2860
Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Serum fatty acid-binding prote ...... nts in end-stage renal disease
@ast
Serum fatty acid-binding prote ...... nts in end-stage renal disease
@en
Serum fatty acid-binding prote ...... nts in end-stage renal disease
@nl
type
label
Serum fatty acid-binding prote ...... nts in end-stage renal disease
@ast
Serum fatty acid-binding prote ...... nts in end-stage renal disease
@en
Serum fatty acid-binding prote ...... nts in end-stage renal disease
@nl
prefLabel
Serum fatty acid-binding prote ...... nts in end-stage renal disease
@ast
Serum fatty acid-binding prote ...... nts in end-stage renal disease
@en
Serum fatty acid-binding prote ...... nts in end-stage renal disease
@nl
P2093
P2860
P3181
P1433
P1476
Serum fatty acid-binding prote ...... nts in end-stage renal disease
@en
P2093
Gökhan S Hotamisligil
Hideaki Yoshida
Hideki Ota
Kazuaki Shimamoto
Manabu Hayashi
Marenao Tanaka
Masato Furuhashi
Shutaro Ishimura
Takahiro Nishitani
Tetsuji Miura
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0027356
P407
P577
2011-01-01T00:00:00Z